Australia · Delayed Price · Currency is AUD Sonic Healthcare Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 5% organically in H1 FY2026, with strong results in Australia, Germany, and the UK. EBITDA margin improved, guidance was reaffirmed, and capital management initiatives—including property sales and potential buybacks—are underway.
Fiscal Year 2025
-
The meeting marked a major leadership transition, reviewed solid financial results, and reaffirmed a focus on medical leadership, sustainability, and disciplined growth. Shareholders approved all resolutions and received updates on acquisitions, dividends, and ongoing strategic priorities.
-
Revenue and EBITDA both grew 8% year-over-year, with strong cash generation and margin expansion. FY 2026 guidance anticipates up to 19% EPS growth, driven by organic growth and recent acquisitions, while integration and synergy capture are underway across key geographies.
-
Strong half-year results with 8% revenue and 17% net profit growth, driven by organic expansion, cost control, and recent acquisitions. Margin expansion and robust cash flow support positive guidance, with major synergies expected from the Kramer Group acquisition and ongoing operational improvements.
Fiscal Year 2024
-
The meeting highlighted strong base business growth, ongoing integration of major acquisitions, and a continued focus on digital and AI-driven transformation. All resolutions passed, with board renewal and cost management initiatives set to drive future margin and earnings improvements.
-
FY 2024 saw strong organic growth, major acquisitions, and a return to margin expansion, with EBITDA of AUD 1.602 billion and a 2% dividend increase. Guidance for FY 2025 targets up to 10% EBITDA growth, supported by easing inflation and integration of recent acquisitions.